Posted in Business News Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma Editor February 15, 2020 Please leave this field emptyGet every new post delivered right to your inbox. Email * Check your inbox or spam folder to confirm your subscription. Original Source
